Association of IL-10 and CCL5 single nucleotide polymorphisms with tuberculosis in the Sudanese population

Tropical Medicine and International Health

Volumn 18, Issue 9, 2013, Pages 1119-1127

  Mhmoud, Najwa ^a   Fahal, Ahmed ^a   Van De Sande, Wendy W J ^b  

^a UNIVERSITY OF KHARTOUM   (Sudan)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Mycobacterium; PCR RFLP; Susceptibility; TB

Indexed keywords

ETHAMBUTOL; GENOMIC DNA; INTERLEUKIN 10; ISONIAZID; PYRAZINAMIDE; RANTES; RIFAMPICIN;

ALLEE EFFECT; BACTERIUM; GENOTYPE; HEALTH SERVICES; MEDICAL GEOGRAPHY; POLYMERASE CHAIN REACTION; POLYMORPHISM; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA ISOLATION; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM CULTURE; SUDAN; TREATMENT DURATION; TUBERCULOSIS;

MYCOBACTERIUM; PCR-RFLP; SUSCEPTIBILITY; TB;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; CASE-CONTROL STUDIES; CHEMOKINE CCL5; DNA, BACTERIAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SPUTUM; SUDAN; TUBERCULOSIS; YOUNG ADULT;

SUDAN;

MYCOBACTERIUM;

EID: 84881669143     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/tmi.12141     Document Type: Article

References (43)

1. Andersen V, Ernst A, Christensen J et al. (2010) The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Medical Genetics 11, 82.
2. Ates O, Musellim B, Ongen G & Topal-Sarikaya A (2008) Interleukin-10 and tumor necrosis factor-alpha gene polymorphisms in tuberculosis. Journal of Clinical Immunology 28, 232-236.
3. Balloy V & Chignard M (2009) The innate immune response to Aspergillus fumigatus. Microbes and Infection 11, 919-927.
4. Ben-Selma W, Harizi H, Bougmiza I, Ben Kahla I, Letaief M, Boukadida J (2011a) Polymorphisms in the RANTES gene increase susceptibility to active tuberculosis in Tunisia. DNA and Cell Biology 30, 789-800.
5. Ben-Selma W, Harizi H & Boukadida J (2011b) Association of TNF-alpha and IL-10 polymorphisms with tuberculosis in Tunisian populations. Microbes and Infection 13, 837-843.
6. Bozzi A, Pereira PP, Reis BS et al. (2006) Interleukin-10 and tumor necrosis factor-alpha single nucleotide gene polymorphism frequency in paracoccidioidomycosis. Human Immunology 67, 931-939.
7. Cardona PJ, Gordillo S, Diaz J et al. (2003) Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infection and Immunity 71, 5845-5854.
8. Chensue SW, Warmington KS, Allenspach EJ et al. (1999) Differential expression and cross-regulatory function of RANTES during mycobacterial (type 1) and schistosomal (type 2) antigen-elicited granulomatous inflammation. The Journal of Immunology 163, 165-173.
9. Chu SF, Tam CM, Wong HS, Kam KM, Lau YL & Chiang AK (2007) Association between RANTES functional polymorphisms and tuberculosis in Hong Kong Chinese. Genes and Immunity 8, 475-479.
10. Costa DL, Dias-Melicio LA, Acorci MJ et al. (2007) Effect of interleukin-10 on the Paracoccidioides brasiliensis killing by gamma-interferon activated human neutrophils. Microbiology and Immunology 51, 73-80.
11. Eid NA, Hussein AA, Elzein AM et al. (2010) Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. Malaria Journal 9, 119.
12. Flynn JL & Chan J (2001) Immunology of tuberculosis. Annual Review of Immunology 19, 93-129.
13. Forte GI, Scola L, Misiano G et al. (2009) Relevance of gamma interferon, tumor necrosis factor alpha, and interleukin-10 gene polymorphisms to susceptibility to Mediterranean spotted fever. Clinical and Vaccine Immunology 16, 811-815.
14. Giampaglia CM, Martins MC, Inumaru VT, Butuem IV & Telles MA (2005) Evaluation of a rapid differentiation test for the Mycobacterium tuberculosis complex by selective inhibition with rho-nitrobenzoic acid and thiophene-2-carboxylic acid hydrazide. The International Journal of Tuberculosis and Lung Disease 9, 206-209.
15. Henao MI, Montes C, Paris SC & Garcia LF (2006) Cytokine gene polymorphisms in Colombian patients with different clinical presentations of tuberculosis. Tuberculosis (Edinb) 86, 11-19.
16. Jakubaschk C (2002) Acacia senegal, soil organic carbon and nitrogen contents: a study in North Kordofan, Sudan. Lunds Universitets instituion för Naturgeografi och Ekosystemanalys, Seminarieuppsatser nr 91. Lunds Universitets instituion för Naturgeografi och Ekosystemanalys, Lund, Sweden, pp. 1-55.
17. Lamden K, Cheesbrough J & Madi S (2000) Detecting tuberculosis in new arrivals to UK. Occupational health screening of doctors must be improved. BMJ 321, 569.
18. Liang L, Zhao YL, Yue J et al. (2011) Interleukin-10 gene promoter polymorphisms and their protein production in pleural fluid in patients with tuberculosis. FEMS Immunology and Medical Microbiology 62, 84-90.
19. Lima MF, Zhang Y & Villalta F (1997) Beta-chemokines that inhibit HIV-1 infection of human macrophages stimulate uptake and promote destruction of Trypanosoma cruzi by human macrophages. Cellular and Molecular Biology (Noisy-le-grand), 43, 1067-1076.
20. Liu H, Chao D, Nakayama EE et al. (1999) Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proceedings of the National Academy of Sciences of the United States of America 96, 4581-4585.
21. Ma MJ, Xie LP, Wu SC et al. (2010) Toll-like receptors, tumor necrosis factor-alpha, and interleukin-10 gene polymorphisms in risk of pulmonary tuberculosis and disease severity. Human Immunology 71, 1005-1010.
22. Mishra G, Poojary SS, Raj P & Tiwari PK (2012) Genetic polymorphisms of CCL2, CCL5, CCR2 and CCR5 genes in Sahariya tribe of North Central India: an association study with pulmonary tuberculosis. Infection, Genetics and Evolution 12, 1120-1127.
23. Osborne CM (1995) The challenge of diagnosing childhood tuberculosis in a developing country. Archives of Disease in Childhood 72, 369-374.
24. Qin X, He Z, Zhao D, Li L & Yuan L (2011) The RANTES gene promoter polymorphisms are associated with the risk of atherothrombotic cerebral infarction in Northern Han Chinese. Clinica Chimica Acta 412, 1112-1115.
25. Ramakrishnan L (2012) Revisiting the role of the granuloma in tuberculosis. Nature Reviews Immunology 12, 352-366.
26. Redford PS, Boonstra A, Read S et al. (2010) Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. European Journal of Immunology 40, 2200-2210.
27. Sanchez-Castanon M, Baquero IC, Sanchez-Velasco P et al. (2009) Polymorphisms in CCL5 promoter are associated with pulmonary tuberculosis in northern Spain. The International Journal of Tuberculosis and Lung Disease 13, 480-485.
28. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J & Kornfeld H (2002) Beta-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infection and Immunity 70, 1684-1693.
29. Selvaraj P, Alagarasu K, Harishankar M, Vidyarani M, Nisha Rajeswari D & Narayanan PR (2008) Cytokine gene polymorphisms and cytokine levels in pulmonary tuberculosis. Cytokine 43, 26-33.
30. Selvaraj P, Alagarasu K, Singh B & Afsal K (2011) CCL5 (RANTES) gene polymorphisms in pulmonary tuberculosis patients of south India. International Journal of Immunogenetics 38, 397-402.
31. Shin HD, Park BL, Kim YH, Cheong HS, Lee IH & Park SK (2005) Common interleukin 10 polymorphism associated with decreased risk of tuberculosis. Experimental & Molecular Medicine 37, 128-132.
32. Su WL, Perng WC, Huang CH, Yang CY, Wu CP & Chen JH (2010) Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clinical and Vaccine Immunology 17, 223-231.
33. Tian M, Liu F, Wen GY, Shi SY, Chen RH & Zhao DY (2009) Effect of variation in RANTES promoter on serum RANTES levels and risk of recurrent wheezing after RSV bronchiolitis in children from Han, Southern China. European Journal of Pediatrics 168, 963-967.
34. Trajkov D, Trajchevska M, Arsov T et al. (2009) Association of 22 cytokine gene polymorphisms with tuberculosis in Macedonians. The Indian Journal of Tuberculosis 56, 117-131.
35. Tso HW, Ip WK, Chong WP, Tam CM, Chiang AK & Lau YL (2005) Association of interferon gamma and interleukin 10 genes with tuberculosis in Hong Kong Chinese. Genes and Immunity 6, 358-363.
36. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ & Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. European Journal of Immunogenetics 24, 1-8.
37. U.S. StCF (1988) Baseline Report. Um Ruwaba District, North Kordofan Province Sudan Field Office, Khartoum, Sudan.
38. Vesosky B, Rottinghaus EK, Stromberg P, Turner J & Beamer G (2010) CCL5 participates in early protection against Myco-bacterium tuberculosis. Journal of Leukocyte Biology 87, 1153-1165.
39. Wang JY, Chang HC, Liu JL et al. (2012) Expression of toll-like receptor 2 and plasma level of interleukin-10 are associated with outcome in tuberculosis. European Journal of Clinical Microbiology and Infectious Diseases 31, 2327-2333.
40. WHO (ed.) (2007) Global Tuberculosis Control: Surveillance, Planning, Financing. WHO Report 2007. WHO/HTM/TB/2007.376. WHO, Geneva, Switzerland.
41. WHO (ed.) (2011) Sudan, Tuberculosis Profile WHO, Geneva, Switzerland.
42. WHO (2012) Global Tuberculosis Report 2012. World Health Organization, Geneva, Switzerland.
43. Zintzaras E (2010) Impact of Hardy-Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. European Journal of Epidemiology 25, 553-560.